---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-215574"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:00:55.058038+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Galera reports Q2 net loss $14.6M ($0.54/sh); NDA for avasopasem on track by end of 2022

## Summary
- Net loss $14.6M ($0.54 per share) in Q2 2022, compared to $22.4M ($0.88/sh) in Q2 2021.
- R&D expenses $6.7M (down from $16.0M YoY); cash and investments $52.0M as of June 30, 2022.
- Phase 3 ROMAN data: avasopasem reduced SOM incidence and days; NDA submission on track for end of 2022.
- Phase 1 GRECO-1: rucosopasem+SBRT showed 6/7 patients with partial response or stable disease; Phase 2 enrollment completion expected 2H 2023.

## SEC filing metadata
- accession: 0001193125-22-215574
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312522215574/0001193125-22-215574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312522215574/d375942d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-215574
- JSON: https://secwatch.observer/filing/0001193125-22-215574.json
- Plain text: https://secwatch.observer/filing/0001193125-22-215574.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.